Table 1. Demographic characteristics and underlying conditions in 8 patients with H275Y mutation of pandemic (H1N1) 2009 virus, Seattle Cancer Care Alliance, Seattle, Washington, USA, May 1, 2009–April 30, 2010*.

Patient no.	Age, y/sex	BMI	Underlying disease	State of disease	HCT	Recent immunosuppressive therapy	Concurrent illness	Lymphocytes, × 103 cells/L
1†	51/M	20.5	AML	Remission	2 y post–allo-HCT	MMF, tacrolimus	GVHD, renal failure	110
2†	47/F	22.9	AML	Relapse	3 y post–allo-HCT	Chemotherapy 1 mo before influenza dx and 1 d after-dx	None	540
3	50/M	23.3	CML	Remission	9 mo post–allo-HCT	TBI, cyclophosphamide, tacrolimus	GVHD	1,470
4	7/F	18.9	ALL	Relapse	NA	Chemotherapy 2 d after influenza diagnosis; prednisone 1.5 mg/kg/d	None	1,440
5	34/F	38.8	Hogkin lymphoma	Refractory	2 d pre–allo-HCT	TBI, fludarabine, cyclophosphamide	Renal failure	0
6†	17/M	19.5	ALL (T cell)	Remission	3 wk post–allo-HCT	TBI, fludarabine, cyclophosphamide, MMF, CSA, prednisone 0.5 mg/kg/d	CMV, GVHD	154
7	17/M	22.4	Osteosarcoma	Relapse	NA	Chemotherapy 1 d before influenza diagnosis	Lung metastasis, thoracotomy, restrictive syndrome	366
8	8/F	14.5	Aplastic anemia	Treatment	NA	ATG, CSA maintenance	None	1,145

*BMI, body mass index; HCT, hemopoietic cell transplant; AML, acute myeloblastic leukemia; allo, allogenic; MMF, mycophenolate mofetil; GVHD, graft-versus-host disease; NA, not applicable; CML, chronic myeloblastic leukemia; TBI, total body irradiation; ALL, acute lymphoblastic leukemia; CSA, cyclosporine; CMV, cytomegalovirus; ATG, antithymocyte globuline.
†Patients previously reported in references (5,13).